Welcome to Xenon

Xenon is a world leading clinical genetics-based drug development company.

Our products are innovative drugs with the potential to transform patient care in pain, diabetes, and disorders of iron metabolism. The drug targets for these products are known to exert a major effect on the disease of interest as they were identified using both human and murine genetic studies. Our programs are a mix of partnered and unpartnered products. Partnered programs include SCD1 inhibitors for metabolic diseases with Novartis, and HJV antagonists for anemia of inflammation with Roche.

News...

October 20, 2009 - Xenon and CDRD's Commercial Arm, DDI, Announce Strategic R&D Collaboration

September 29, 2009 - Xenon shoots and scores in genetics-based drug discoveries

June 11, 2009 - Xenon enters into cardiovascular disease collaboration with Merck

June 17, 2008 - Xenon receives BIOTECanada Gold Leaf Award

Xenon is hiring - check our current postings